Silexion’s SIL-204 Shows Synergy Against KRAS-Driven Cancers
Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech company, has released promising preclinical data for SIL-204, its next-generation RNA interference...
Jon Napitupulu
Rubedo Life Sciences Announces Clinical Development Plans for Lead Candidate RLS-1496
Rubedo Life Sciences announced clinical development plans for RLS-1496, a first-in-class GPX4 modulator targeting aging cells, at the 12th...
Omeros Announces Narsoplimab Trial Endpoint Update
Omeros Corporation announced positive sensitivity analysis results for narsoplimab, its monoclonal antibody targeting the lectin pathway of complement, in...
Micron Biomedical Secures $33M for Needle-Free Delivery
Micron Biomedical secured $16 million in a Series A3 funding round, bringing the total Series A investment to over...
Africa CDC-Led Mpox Therapeutic Study Begins Enrollment
The first patients have been enrolled in the MOSA trial, a pivotal clinical trial evaluating treatments for Mpox (formerly...
Complete 12-Week Results of NORSE Eight Trial for Outlook Therapeutics®
Outlook Therapeutics announced positive 12-week results from its NORSE EIGHT trial for ONS-5010, an ophthalmic bevacizumab formulation for wet...
Scaling Cell & Gene Therapies Globally: CGT & Cellex Partnership
CGT Global, a US-based cell collection and expansion company, and Cellex Cell Professionals, a German cell therapy manufacturer, have...
ImmunityBio’s 2025 FDA Submissions After Agency Meeting
ImmunityBio announced progress in discussions with the FDA concerning its non-muscle invasive bladder cancer (NMIBC) and non-small cell lung...
Solid Biosciences: Advancing Neuromuscular and Cardiac Gene Therapy
Solid Biosciences provided a corporate update highlighting its expanded clinical pipeline and 2025 objectives, focusing on genetic medicines for...
SIL-204 Shows Synergy with Chemotherapies in Preclinical Pancreatic Cancer Study
Silexion Therapeutics (NASDAQ: SLXN) announced promising preclinical results for SIL-204, its second-generation siRNA therapy targeting KRAS-mutated cancers. The data...